{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:13:00Z","timestamp":1794276780470,"version":"4.9.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41571-026-01188-1","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:15:40Z","timestamp":1785399340000},"page":"806-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical toxicity of ADCs and ICI\u2013ADC combinations: mechanisms, patterns and management"],"prefix":"10.1038","volume":"23","author":[{"given":"Solange","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"1188_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/cai2.97","volume":"2","author":"J Li","year":"2023","unstructured":"Li, J. et al. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer Innov. 2, 346\u2013375 (2023).","journal-title":"Cancer Innov."},{"key":"1188_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters, J. C., Nickens, D. J., Xuan, D., Shazer, R. L. & Amantea, M. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest. New Drugs 36, 121\u2013135 (2018).","journal-title":"Invest. New Drugs"},{"key":"1188_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1632705","volume":"16","author":"R Shi","year":"2025","unstructured":"Shi, R., Jia, L., Lv, Z. & Cui, J. Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications. Front. Immunol. 16, 1632705 (2025).","journal-title":"Front. Immunol."},{"key":"1188_CR5","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105573","volume":"10","author":"R Woodford","year":"2025","unstructured":"Woodford, R. et al. Toxicity and efficacy of antibody-drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trials. ESMO Open 10, 105573 (2025).","journal-title":"ESMO Open"},{"key":"1188_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71977-0","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Ren, X., Dai, Y. & Wang, Y. Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system. Sci. Rep. 14, 21386 (2024).","journal-title":"Sci. Rep."},{"key":"1188_CR9","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO-25-02016","volume":"44","author":"S Peters","year":"2026","unstructured":"Peters, S. et al. First-in-human, phase I study of sigvotatug vedotin, an integrin beta-6-directed antibody-drug conjugate: results from dose expansion in advanced non-small cell lung cancer. J. Clin. Oncol. 44, 1635\u20131645 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1188_CR10","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka, A. K. et al. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer 129, 3746\u20133760 (2023).","journal-title":"Cancer"},{"key":"1188_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia, A. et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J. Clin. Oncol. 43, 285\u2013296 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1188_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1188_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655\u2013671.e22 (2020).","journal-title":"Cell"},{"key":"1188_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1200\/OP.23.00097","volume":"19","author":"P Tarantino","year":"2023","unstructured":"Tarantino, P. & Tolaney, S. M. Detecting and managing T-DXd-related interstitial lung disease: the five \u201cS\u201d rules. JCO Oncol. Pract. 19, 526\u2013527 (2023).","journal-title":"JCO Oncol. Pract."},{"key":"1188_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly, H. et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N. Engl. J. Med. 386, 351\u2013363 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000480492","volume":"12","author":"L Kowalczyk","year":"2017","unstructured":"Kowalczyk, L., Bartsch, R., Singer, C. F. & Farr, A. Adverse events of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive breast cancer patients. Breast Care 12, 401\u2013408 (2017).","journal-title":"Breast Care"},{"key":"1188_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00391","volume":"7","author":"M Nishino","year":"2023","unstructured":"Nishino, M. et al. Trastuzumab deruxtecan\u2013related interstitial lung disease\/pneumonitis: computed tomography imaging patterns to guide diagnosis and management. JCO Precis. Oncol. 7, e2300391 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"1188_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell, C. A. et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 7, 100554 (2022).","journal-title":"ESMO Open"},{"key":"1188_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/OP.22.00480","volume":"19","author":"HS Rugo","year":"2023","unstructured":"Rugo, H. S. et al. Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol. Pract. 19, 539\u2013546 (2023).","journal-title":"JCO Oncol. Pract."},{"key":"1188_CR20","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S1470-2045(25)00470-X","volume":"26","author":"R Bartsch","year":"2025","unstructured":"Bartsch, R. et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 26, 1467\u20131478 (2025).","journal-title":"Lancet Oncol."},{"key":"1188_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1200\/JCO-25-02142","volume":"44","author":"CM Rudin","year":"2026","unstructured":"Rudin, C. M. et al. Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 trial. J. Clin. Oncol. 44, 261\u2013273 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1188_CR22","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","volume":"7","author":"P Tarantino","year":"2021","unstructured":"Tarantino, P. et al. Interstitial lung disease induced by anti-erbb2 antibody-drug conjugates: a review. JAMA Oncol. 7, 1873\u20131881 (2021).","journal-title":"JAMA Oncol."},{"key":"1188_CR23","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617\u2013628 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR25","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh, J. D., Isidro-Llobet, A., Parker, J. S. & Spring, D. R. Cleavable linkers in antibody-drug conjugates. Chem. Soc. Rev. 48, 4361\u20134374 (2019).","journal-title":"Chem. Soc. Rev."},{"key":"1188_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon, R. P. et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 33, 733\u2013735 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1188_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy, H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8, 659\u2013671 (2016).","journal-title":"MAbs"},{"key":"1188_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2024024442","volume":"144","author":"RP Taylor","year":"2024","unstructured":"Taylor, R. P. & Lindorfer, M. A. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms. Blood 144, 137\u2013144 (2024).","journal-title":"Blood"},{"key":"1188_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","volume":"39","author":"M Aoyama","year":"2022","unstructured":"Aoyama, M., Tada, M., Yokoo, H., Demizu, Y. & Ishii-Watabe, A. Fcgamma receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates. Pharm. Res. 39, 89\u2013103 (2022).","journal-title":"Pharm. Res."},{"key":"1188_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/antib7010010","author":"AT Lucas","year":"2018","unstructured":"Lucas, A. T. et al. Factors affecting the pharmacology of antibody-drug conjugates. Antibodies https:\/\/doi.org\/10.3390\/antib7010010 (2018).","journal-title":"Antibodies"},{"key":"1188_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano, F., Corti, C., Tarantino, P., Michelini, F. & Curigliano, G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr. Oncol. Rep. 24, 809\u2013817 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"1188_CR32","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher, A. H. & Brown, M. P. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br. J. Cancer 117, 1736\u20131742 (2017).","journal-title":"Br. J. Cancer"},{"key":"1188_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C. & Corvaia, N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug. Discov. 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1188_CR34","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","volume":"66","author":"HK Erickson","year":"2006","unstructured":"Erickson, H. K. et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426\u20134433 (2006).","journal-title":"Cancer Res."},{"key":"1188_CR35","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","volume":"66","author":"YV Kovtun","year":"2006","unstructured":"Kovtun, Y. V. et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66, 3214\u20133221 (2006).","journal-title":"Cancer Res."},{"key":"1188_CR36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nbt.3274","volume":"33","author":"P Strop","year":"2015","unstructured":"Strop, P. et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat. Biotechnol. 33, 694\u2013696 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1188_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowski","year":"2014","unstructured":"Panowski, S., Bhakta, S., Raab, H., Polakis, P. & Junutula, J. R. Site-specific antibody drug conjugates for cancer therapy. MAbs 6, 34\u201345 (2014).","journal-title":"MAbs"},{"key":"1188_CR38","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert, J. M. & Morris, C. Q. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv. Ther. 34, 1015\u20131035 (2017).","journal-title":"Adv. Ther."},{"key":"1188_CR39","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","volume":"161","author":"SC Sasson","year":"2021","unstructured":"Sasson, S. C. et al. Interferon-\u03b3-producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology 161, 1229\u20131244.e9 (2021).","journal-title":"Gastroenterology"},{"key":"1188_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cpt.70060","volume":"119","author":"C Dello Russo","year":"2026","unstructured":"Dello Russo, C., Asiimwe, I. G., Pushpakom, S., Palmieri, C. & Pirmohamed, M. UGT1A1 and sacituzumab govitecan toxicity: a systematic review and meta-analysis. Clin. Pharmacol. Ther. 119, 63\u201373 (2026).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1188_CR41","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","volume":"82","author":"Z Abuhelwa","year":"2022","unstructured":"Abuhelwa, Z., Alloghbi, A., Alqahtani, A. & Nagasaka, M. Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs 82, 979\u2013987 (2022).","journal-title":"Drugs"},{"key":"1188_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102113","volume":"62","author":"A D\u2019Arienzo","year":"2023","unstructured":"D\u2019Arienzo, A. et al. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine 62, 102113 (2023).","journal-title":"EClinicalMedicine"},{"key":"1188_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","volume":"191","author":"KN Moore","year":"2024","unstructured":"Moore, K. N. et al. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor \u03b1-expressing recurrent ovarian cancer: an integrated safety summary. Gynecol. Oncol. 191, 249\u2013258 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1188_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki, C. M. et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat. Commun. 12, 3528 (2021).","journal-title":"Nat. Commun."},{"key":"1188_CR45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"1188_CR46","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. 384, 1125\u20131135 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR47","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng, X. et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J. Clin. Oncol. 42, 1391\u20131402 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1188_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote, I. et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N. Engl. J. Med. 391, 44\u201355 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01785","volume":"10","author":"S Zhu","year":"2020","unstructured":"Zhu, S., Fu, Y., Zhu, B., Zhang, B. & Wang, J. Pneumonitis induced by immune checkpoint inhibitors: from clinical data to translational investigation. Front. Oncol. 10, 1785 (2020).","journal-title":"Front. Oncol."},{"key":"1188_CR50","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2021.03.012","volume":"150","author":"Y Fujiwara","year":"2021","unstructured":"Fujiwara, Y., Horita, N., Namkoong, H. & Galsky, M. D. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials. Eur. J. Cancer 150, 168\u2013178 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1188_CR51","first-page":"358","volume":"17","author":"JG Hashash","year":"2021","unstructured":"Hashash, J. G., Francis, F. F. & Farraye, F. A. Diagnosis and management of immune checkpoint inhibitor colitis. Gastroenterol. Hepatol. 17, 358\u2013366 (2021).","journal-title":"Gastroenterol. Hepatol."},{"key":"1188_CR52","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR53","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.22.02835","volume":"42","author":"P Grivas","year":"2024","unstructured":"Grivas, P. et al. Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3. J. Clin. Oncol. 42, 1415\u20131425 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1188_CR54","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.23.00720","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote, I. et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study. J. Clin. Oncol. 41, 5536\u20135549 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1188_CR55","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng, X. et al. Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. N. Engl. J. Med. 393, 2324\u20132337 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine 68, 102415 (2024).","journal-title":"EClinicalMedicine"},{"key":"1188_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101216","volume":"68","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study. Neoplasia 68, 101216 (2025).","journal-title":"Neoplasia"},{"key":"1188_CR58","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","volume":"200","author":"UA Matulonis","year":"2025","unstructured":"Matulonis, U. A. et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. Gynecol. Oncol. 200, 96\u2013104 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1188_CR59","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1002\/cncr.35319","volume":"130","author":"A Suvannasankha","year":"2024","unstructured":"Suvannasankha, A. et al. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma. Cancer 130, 2629\u20132641 (2024).","journal-title":"Cancer"},{"key":"1188_CR60","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch, E. et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J. Clin. Oncol. 34, 557\u2013565 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1188_CR61","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch, E. et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318, 197\u2013198 (2017).","journal-title":"JAMA"},{"key":"1188_CR62","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11523-020-00739-5","volume":"15","author":"LC Kennedy","year":"2020","unstructured":"Kennedy, L. C. et al. Untangling the multidisciplinary care web: streamlining care through an immune-related adverse events (IRAE) tumor board. Target. Oncol. 15, 541\u2013548 (2020).","journal-title":"Target. Oncol."},{"key":"1188_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70096","volume":"13","author":"MH Wong","year":"2024","unstructured":"Wong, M. H. et al. UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan. Cancer Med. 13, e70096 (2024).","journal-title":"Cancer Med."},{"key":"1188_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634","volume":"11","author":"A Wahab","year":"2021","unstructured":"Wahab, A. et al. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front. Oncol. 11, 678634 (2021).","journal-title":"Front. Oncol."},{"key":"1188_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102867","volume":"134","author":"B Bouguerra Zina","year":"2025","unstructured":"Bouguerra Zina, B., Rousseau, F., Fauquier, S., Sabatier, R. & Kfoury, M. Practical clinical management of ocular adverse events related to antibody-drug conjugates in gynaecological malignancies. Cancer Treat. Rev. 134, 102867 (2025).","journal-title":"Cancer Treat. Rev."},{"key":"1188_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E Basch","year":"2014","unstructured":"Basch, E. et al. Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J. Natl Cancer Inst. 106, dju244 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"1188_CR67","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","volume":"33","author":"M Di Maio","year":"2022","unstructured":"Di Maio, M. et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. Ann. Oncol. 33, 878\u2013892 (2022).","journal-title":"Ann. Oncol."},{"key":"1188_CR68","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_438512","volume":"44","author":"J Lai-Kwon","year":"2024","unstructured":"Lai-Kwon, J., Thorner, E., Rutherford, C., Crossnohere, N. & Brundage, M. Integrating patient-reported outcomes into the care of people with advanced cancer \u2014 a practical guide. Am. Soc. Clin. Oncol. Educ. Book. 44, e438512 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"1188_CR69","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","volume":"30","author":"E Hamilton","year":"2024","unstructured":"Hamilton, E. et al. Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study. Clin. Cancer Res. 30, 5548\u20135558 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1188_CR70","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney, S. M. et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N. Engl. J. Med. 394, 354\u2013366 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1188_CR71","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1188_CR72","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1200\/JCO.19.00320","volume":"37","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih, H. et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J. Clin. Oncol. 37, 2738\u20132745 (2019).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01188-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:02:08Z","timestamp":1789732928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01188-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01188-1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"14 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.P. works in an institution that has had grants or contracts with Amgen, Arcus, AstraZeneca, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech, GSK, iTeos, Mirati, MSD, Mirati, Pharma Mar, Pfizer, Promontory Therapeutics, Roche and Seattle Genetics; received consulting fees paid to her institution by AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BioNTech, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F-Star, Foundation Medicine, Genentech, Genmab, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Qlucore, Merck Serono, Merrimack, Mirati, MSD, Nuvation Bio, Nykode Therapeutics, Novartis, Novocure, Pharma Mar, Promontory Therapeutics, Pfizer, Regeneron, Roche, Sanofi, Seattle Genetics, Takeda and Zymeworks; received payment or honoraria paid to her institution by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Foundation Medicine, Genentech, GSK, Illumina, Ipsen, Mirati, MSD, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics and Takeda; received travel fees paid to her institution from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, MSD, Novartis, Pfizer, Roche and Takeda; has participated on data safety monitoring boards or advisory boards for AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BioNTech, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F-Star, Foundation Medicine, Genentech, Genmab, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Qlucore, Merck Serono, Merrimack, Mirati, MSD, Nuvation Bio, Nykode Therapeutics, Novartis, Novocure, Pharma Mar, Promontory Therapeutics, Pfizer, Regeneron, Roche, Sanofi, Seattle Genetics, Takeda and Zymeworks; and participates in the board of directors of Galenica SA. P.G. has been a consultant for Abbvie, Astellas Pharma, AstraZeneca, Bayer, Bicycle Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, EMD Serono, Foundation Medicine, Gilead Sciences, Janssen, MSD, Natera, Ottimo Pharma, Pfizer, Replimune, Roche, Strata Oncology, Tyra Biosciences and Urogen; and works in an institution that has received research funding from Acrivon Therapeutics, ALX Oncology, EMD Serono, Genentech, Gilead Sciences and MSD. C.M. has received grants and personal fees from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Eli Lilly, MedImmune, MSD, Novartis, Orion, Pfizer, Roche and Sanofi; and has been a principal investigator or sub-investigator in clinical trials sponsored by numerous companies including AbbVie, AstraZeneca, Bayer, BeiGene, BMS, Boehringer Ingelheim, Celgene, Daiichi Sankyo, GSK, Incyte, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda. S.M.T. has received personal fees from Aktis Oncology, Artios Pharma, Arvinas, AstraZeneca, Avenzo Therapeutics, Bayer, BeiGene, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb, Celcuity, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, Denali Therapeutics, Eisai, Eli Lilly, Genentech, Gilead, Jazz Pharmaceuticals, Johnson & Johnson\u2013Ambrx, Launch Therapeutics, Menarini\u2013Stemline, Merck, Mersana, Novartis, Olema Pharmaceuticals, Pfizer, Relay Therapeutics, Reveal Genomics, Roche, Samsung Bioepis, SeaGen, Summit Therapeutics, Systimmune, Tempus and Zuellig Pharma; and has received grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech, Gilead, Jazz Pharmaceuticals, Lilly, Menarini\u2013Stemline, NanoString Technologies, Novartis, Olema Pharmaceuticals, OncoPep, Pfizer, Merck, Roche and SeaGen outside the submitted work. M.O. has been a consultant, attended advisory board meetings and\/or provided lectures for Bristol Myers Squibb, F. Hoffmann-La Roche, Moderna and Pfizer.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}